nach oben

Erschienen in:

01.06.2010 | Urology - Original Paper

Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis

verfasst von: Omer Kutlu, Erdem Akkaya, Ismail Turker Koksal, Ibrahim Cumhur Bassorgun, Mehmet Akif Ciftcioglu, Salih Sanlioglu, Erdal Kukul

Erschienen in: International Urology and Nephrology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Although interstitial cystitis is an inflammatory disease, its etiopathogenesis is not clearly understood. The objective of the present study is to investigate the distribution of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in bladder biopsy samples of patients diagnosed with interstitial cystitis and the role of TRAIL in the pathogenesis of interstitial cystitis.

Materials and methods

TRAIL and its receptors were stained immunohistochemically in bladder biopsy samples of 27 patients diagnosed with interstitial cystitis, and the samples were evaluated independently by two pathologists and were scored in terms of expression intensity and distribution.

Results

An evaluation of the results of the statistical analysis showed that the TRAIL-R4 receptor was immunohistochemically stained with a higher score than TRAIL-R1, TRAIL-R2, TRAIL-R3 receptors and TRAIL, with a statistically significant difference (P < 0.05).

Conclusion

These findings indicate that TRAIL-R4 is the predominant receptor in the interstitial cystitis inflammation.

Hanno PM, Landis JR, Matthews-Cook Y et al (1999) The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol 161(2):553–557CrossRefPubMed

Oravisto KJ (1975) Epidemiology of interstitial cystitis. Ann Chir Gynaecol Fenn 64:75–77PubMed

Curhan GC, Speizer FE, Hunter DJ (1999) Epidemiology of interstitial cystitis: a population based study. J Urol 161(2):549–552CrossRefPubMed

Leppilahti M, Tammela TL, Huhtala H et al (2002) Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland. J Urol 168(1):139–143CrossRefPubMed

O’Leary MP, Sant GR, Fowler FJ Jr et al (1997) The interstitial cystitis symptom index and problem index. Urology 49(5A):58–63CrossRefPubMed

Shea-O’Malley CC, Sant GR (1999) Quality of life in interstitial cystitis. Urol Intregrada Invest 4:303–306

Parsons CL, Lilly JD, Stein P (1991) Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 145(4):732–735PubMed

Parsons CL, Stein PC, Bidair M et al (1994) Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn 13(5):515–520CrossRefPubMed

Parsons CL, Forrest J, Nickel JC et al (2002) Elmiron Study Group. Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology 59(3):329–333CrossRefPubMed

10.

Lewis SA, Diamond JM (1976) Na+ transport by rabbit urinary bladder, a tight epithelium. J Membr Biol 28(1):1–40CrossRefPubMed

11.

Eldrup J, Thorup J, Nielsen SL et al (1983) Permeability and ultrastructure of human bladder epithelium. Br J Urol 55(5):488–492CrossRefPubMed

12.

Trelstad RL (1985) Glycosaminoglycans: mortar, matrix, mentor. Lab Invest 53:l–l4

13.

Cornish J, Nickel JC, Vanderwee M et al (1990) Ultrastructural visualization of human bladder mucous. Urol Res 18:263–264CrossRefPubMed

14.

Ruoslahti E (1988) Structure and biology of proteoglycans. Annu Rev Cell Biol 4:229–232CrossRefPubMed

15.

Gill WB, Jones KW, Ruggiero KJ (1982) Protective effects of heparin and other sulfated glycosaminoglycans on crystal adhesion to injured urothelium. J Urol 127(1):152–154PubMed

16.

Parsons CL, Mulholland SG, Anwar H (1979) Antibacterial activity of bladder surface mucin duplicated by exogenous glycosaminoglycan (heparin). Infect Immun 24(2):552–557PubMed

17.

Hohlbrugger G (1995) The vesical blood-urine barrier: a relevant and dynamic interface between renal function and nervous bladder control. J Urol 154(1):6–15CrossRefPubMed

18.

Hohlbrugger G, Lentsch P, Pfaller K et al (1985) Permeability characteristics of the rat urinary bladder in experimental cystitis and after overdistension. Urol Int 40(4):211–216CrossRefPubMed

19.

Saban R, Keith IM, Bjorling DE (1997) Neuropeptide-mast cell interaction in interstitial cystitis. In: Sant GR (ed) Interstitial cystitis. Lippincott–Raven, Philadelphia, pp 53–66

20.

Theoharides TC, Sant GR (1991) Bladder mast cell activation in interstitial cystitis. Semin Urol 9(2):74–87PubMed

21.

Theoharides TC, Pang X, Letourneau R et al (1998) Interstitial cystitis: a neuroimmunoendocrine disorder. Ann NY Acad Sci 840:619–634CrossRefPubMed

22.

Abdel-Mageed AB, Ghoniem GM (1998) Potential role of rel/nuclear factor-kappaB in the pathogenesis of interstitial cystitis. J Urol 160(6):2000–2003CrossRefPubMed

23.

Nazif O, Teichman JM, Gebhart GF (2007) Neural upregulation in interstitial cystitis. Urology 69(4):24–33CrossRefPubMed

24.

Sadhukhan PC, Tchetgen MB, Rackley RR et al (2002) Sodium pentosan polysulfate reduces urothelial responses to inflammatory stimuli via an indirect mechanism. J Urol 168(1):289–292CrossRefPubMed

25.

Nesterov A, Lu X, Johnson M et al (2001) Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276(14):10767–10774CrossRefPubMed

26.

Degli-Esposti MA, Dougall WC, Smolak PJ et al (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7(6):813–820CrossRefPubMed

27.

Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 6:673–682CrossRef

28.

Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA et al (2003) Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 4(3):255–260CrossRefPubMed

29.

Wang XC, Saban R, Kaysen JH et al (2000) Nuclear factor kappa B mediates lipopolysaccharide-induced inflammation in the urinary bladder. J Urol 163(3):993–998CrossRefPubMed

30.

Lynes WL, Flynn SD, Shortliffe LD et al (1987) Mast cell involvement in interstitial cystitis. J Urol 138:746–752PubMed

31.

Berent-Maoz B, Piliponsky AM, Daigle I et al (2006) Human mast cells undergo TRAIL-induced apoptosis. J Immunol 176(4):2272–2278PubMed

32.

Renshaw SA, Parmar JS, Singleton V et al (2003) Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 170(2):1027–1033PubMed

33.

Zamai L, Ahmad M, Bennett IM et al (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188(12):2375–2380CrossRefPubMed

34.

Sedger LM, Glaccum MB, Schuh JC et al (2002) Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 32(8):2246–2254CrossRefPubMed

35.

Ludwig AT, Moore JM, Luo Y et al (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64(10):3386–3390CrossRefPubMed

36.

Kimberley FC, Screaton GR (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res 14(5):359–372CrossRefPubMed

37.

Hu WH, Johnson H, Shu HB (1999) Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274(43):30603–30610CrossRefPubMed

38.

Koksal IT, Sanlioglu AD, Karacay B et al (2008) Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 26(2):158–165PubMed

39.

Sanlioglu AD, Koksal IT, Ciftcioglu A et al (2007) Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol 177(1):359–364CrossRefPubMed

40.

Griffith TS, Anderson RD, Davidson BL et al (2000) Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 165(5):2886–2894PubMed

41.

Takayanagi H, Juji T, Miyazaki T et al (1999) Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 104(2):137–146CrossRefPubMed

42.

Terzioglu E, Bisgin A, Sanlioglu AD et al (2007) Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 46(5):783–789CrossRef

43.

Sanlioglu AD, Koksal IT, Karacay B et al (2006) Adenovirus-mediated IKKβ expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 13(1):21–31CrossRefPubMed

44.

Franco AV, Zhang XD, Van Berkel E et al (2001) The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166(9):5337–5345PubMed

45.

Lamhamedi-Cherradi SE, Zheng SJ, Tisch RM et al (2003) Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52:2274–2278CrossRefPubMed

46.

Sato K, Nakaoka T, Yamashita N et al (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol 174:4025–4033PubMed

47.

Dirice E, Sanlioglu AD, Kahraman S et al. (2009) Adenovirus mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in STZ-induced diabetic rats. Hum Gene Ther doi:10.1089/hum.2009.039

Titel: Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis
verfasst von: Omer Kutlu
Erdem Akkaya
Ismail Turker Koksal
Ibrahim Cumhur Bassorgun
Mehmet Akif Ciftcioglu
Salih Sanlioglu
Erdal Kukul
Publikationsdatum: 01.06.2010
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 2/2010
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-009-9632-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Hyperoxaluria after modern bariatric surgery: case series and literature review

The dark side of high-intensity renal replacement therapy of acute kidney injury in critically ill patients

Clinical and metabolic risk factor evaluation in young adults with kidney stones

Incidence of end-stage renal disease in the elderly: a steadily rising global socioeconomic epidemic

Modified ureteroneocystostomy in kidney transplantation to facilitate endoscopic management of subsequent urological complications

Genetic variation of apolipoprotein E does not contribute to the lipid abnormalities secondary to childhood minimal change nephrotic syndrome